Savvy Psychopharmacology

Prazosin for PTSD: Sorting out the evidence

Author and Disclosure Information

 

References

A major theme of studies evaluating prazosin treatment for PTSD is a focus on a military population and military-related trauma. Other than Taylor et al12 (N=13), none of these trials included patients who were diagnosed with PTSD due to other traumas, such as sexual trauma, which limits the generalizability of the results. Furthermore, apart from the PACT trial, none of these studies had >100 participants, which further reduces external validity. Current guidelines have not been updated to include the results of the PACT trial, and it is unclear if the results of this trial are strong enough to change clinical practice.

CASE CONTINUED

To ensure patient-centered care, the treating clinicians conduct a risk/benefit discussion with the patient regarding starting prazosin. Mr. H opts to try prazosin, so the clinicians initiate a low dose (1 mg/d) to mitigate adverse effects, and plan to titrate to clinical effect or intolerability. Per evidence from the trials discussed, it is likely Mr. H will need to be titrated to at least 5 to 6 mg/d to see a clinical effect.

Related Resource

North CS, Hong BA, Downs DL. PTSD: A systematic approach to diagnosis and treatment. Current Psychiatry 2018;17(4):35-43.

Drug Brand Names

Fluoxetine • Prozac
Prazosin • Minipress

Pages

Recommended Reading

Step therapy: Inside the fight against insurance companies and fail-first medicine
MDedge Psychiatry
COVID-19 ‘long-haul’ symptoms overlap with ME/CFS
MDedge Psychiatry
Child abuse tied to persistent inflammation in later life
MDedge Psychiatry
High-dose lumateperone: A case report
MDedge Psychiatry
Switching antipsychotics: A guide to dose equivalents
MDedge Psychiatry
Your patient refuses a suicide risk assessment. Now what?
MDedge Psychiatry
National Psoriasis Foundation recommends some stop methotrexate for 2 weeks after J&J vaccine
MDedge Psychiatry
Rhythm and blues: Using heart rate to diagnose depression
MDedge Psychiatry
Vaccine mismatch: What to do after dose 1 when plans change
MDedge Psychiatry
CDC adds new medical conditions to COVID-19 high-risk list
MDedge Psychiatry